Eloralintide
Eloralintide (also called LY3841136, LY-3841136) is an investigational once-weekly selective amylin receptor agonist developed by Eli Lilly, in Phase 3 trials for obesity since February 2026.
Also known as LY3841136, LY-3841136
Peptigrity has 8 lab tests of eloralintide on file from 7 shops and 3 labs; the newest is from . Average HPLC purity is 99.59% across the 7 results that report it, and 85.7% of results are at or above 99%. 7 results compare the measured amount with the label (median 105.5% of label); 2 report endotoxin. 7 shops publish prices: $7.40 to $30.00 per mg, median $15.80. Peptigrity publishes measurements, not dosing advice.
From Peptigrity records · figures updated · Cite these figures
Lab test results
| Tested | Shop | Lab | Purity | Measured vs label | Endotoxin | Record |
|---|---|---|---|---|---|---|
| Shop withheld | Freedom Diagnostics | 99.93% | not reported | — | View record → | |
| Shop withheld | Freedom Diagnostics | 99.65% | 5.48 / 5 mg 110% of label | — | View record → | |
| Shop withheld | ILS Laboratories | 98.82% | 10.55 / 10 mg 106% of label | — | P1ELO09✓ | |
| Shop withheld | Freedom Diagnostics | 99.59% | 10.73 / 10 mg 107% of label | Pass | ERA1007222026 | |
| Shop withheld | Freedom Diagnostics | 99.86% | 4.42 / 5 mg 88% of label | Pass | 105-01-RB✓ | |
| Shop withheld | ILS Laboratories | 99.82% | 10.38 / 10 mg 104% of label | — | GL-010204✓ | |
| Shop withheld | Freedom Diagnostics | 99.87% | 9.99 / 10 mg 100% of label | — | EL010042526✓ | |
| Shop withheld | Janoshik Labs | 99.52% | 13.78 / 10 mg 138% of label | — | EL010-0425 |
Shops listing Eloralintide
During active brand-owner enforcement we publish market-level pricing only and do not attribute offers to individual shops.
Market-level pricing for Eloralintide — lowest and median per milligram, size bands and 90-day history — is published in full.
See Eloralintide prices →Peptigrity is not affiliated with or endorsed by any manufacturer.
What is Eloralintide?
Eloralintide, also designated LY3841136, is Eli Lilly's investigational long-acting amylin analog: a synthetic peptide modeled on amylin, the hormone the pancreas releases with insulin after meals, with a fatty-acid chain added so it can be injected once a week. Where cagrilintide acts on amylin and calcitonin receptors alike, eloralintide was designed to prefer the amylin receptors. After a 48-week Phase 2 trial published in The Lancet in November 2025, Lilly began Phase 3 trials for obesity in February 2026, and in September 2026 it reported Phase 2b results for eloralintide combined with tirzepatide in people with obesity and type 2 diabetes. Eloralintide is not approved and not commercially available anywhere as of November 2026.
Sources: Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight, Eli Lilly and Company, via Eli Lilly and Company (company release, 6 Nov 2025); Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial, Billings L.K., Hsia S., Bays H., et al., Lancet, 2025; ENLIGHTEN-1: eloralintide in adults with obesity or overweight without type 2 diabetes (NCT07321886), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in adults with obesity or overweight and type 2 diabetes (NCT07282600), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in obesity that persists on incretin therapy (NCT07392190), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes, Eli Lilly and Company, via Eli Lilly and Company (company release, 30 Sep 2026)
Eloralintide formula and molecular weight
Eloralintide has the formula C201H319N49O65S2 and a molecular weight of 4,526.16 Da (CAS 2883634-40-8).
| Molecular formula | C201H319N49O65S2 |
|---|---|
| Molecular weight | 4,526.16 DaA certificate that includes mass spectrometry reports the mass it measured. Compare it with this figure. |
| CAS number | 2883634-40-8 |
| Also known as | LY3841136 · LY-3841136 |
What is eloralintide and how does it work?
Amylin slows how quickly the stomach empties, adds to the feeling of fullness and lowers glucagon after meals, so people eat less. It acts through amylin receptors, which are the calcitonin receptor paired with a helper protein called RAMP (known as AMY1, AMY2 and AMY3), and more weakly through the calcitonin receptor on its own. Eloralintide was engineered to prefer the amylin receptors: Lilly reports it is about 12 times more potent at the human AMY1 receptor than at the calcitonin receptor. Natural amylin is short-lived in the blood; eloralintide carries a C20 fatty diacid chain that extends its action enough for a once-weekly injection. It does not act directly on GLP-1, GIP or glucagon receptors, so it works through a different pathway from semaglutide, tirzepatide and retatrutide, which is one reason Lilly is also testing it alongside tirzepatide. In Lilly's rat studies, eloralintide reduced food intake and body weight, mostly through fat loss, with weak taste aversion, a laboratory stand-in for nausea.
Sources: Is eloralintide a selective amylin receptor agonist?, Lilly Medical Information, via Lilly Medical Information (medical information answer); Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept, Briere D.A., Qu H., Lansu K., et al., Mol Metab, 2025
What does the clinical evidence show?
Phase 1 studies in healthy volunteers and in people with obesity or overweight came first (Briere et al., 2025; Bhattachar et al., 2026). In the Phase 2 trial, 263 adults at 46 US sites, with obesity, or overweight plus a weight-related condition, and without type 2 diabetes, received once-weekly eloralintide at one of four fixed doses (1, 3, 6 or 9 mg) or one of two step-up schedules, or placebo, for 48 weeks. Mean weight loss ranged from 9.5% on 1 mg to 20.1% on 9 mg, against 0.4% on placebo (estimates assuming all participants adhered to treatment); counting everyone randomized, whether or not they stayed on treatment, the range was 7.3% to 17.5%, against 2.3%. In the 9 mg group, 57% lost at least 20% of their body weight, and waist circumference, blood pressure, blood lipids, blood sugar and markers of inflammation improved. Phase 3 began in February 2026 with ENLIGHTEN-1 (about 1,980 adults with obesity or overweight and without type 2 diabetes, with a 75-week main phase), alongside trials in about 1,035 adults with type 2 diabetes and in about 900 people whose obesity persists on an incretin medicine; no Phase 3 results have been reported as of November 2026. With tirzepatide, in a 48-week Phase 2b trial in adults with obesity or overweight and type 2 diabetes, the highest-dose combination produced 23.3% average weight loss, more than either drug alone, with more gastrointestinal side effects. Lilly calls the combination EloraTZP and plans Phase 3 trials of a single-injection version by the end of 2026.
Sources: Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial, Billings L.K., Hsia S., Bays H., et al., Lancet, 2025; Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight, Eli Lilly and Company, via Eli Lilly and Company (company release, 6 Nov 2025); Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept, Briere D.A., Qu H., Lansu K., et al., Mol Metab, 2025; Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept, Bhattachar S. et al., Diabetes Obes Metab, 2026; ENLIGHTEN-1: eloralintide in adults with obesity or overweight without type 2 diabetes (NCT07321886), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in adults with obesity or overweight and type 2 diabetes (NCT07282600), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in obesity that persists on incretin therapy (NCT07392190), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes, Eli Lilly and Company, via Eli Lilly and Company (company release, 30 Sep 2026) · Evidence level: phase 2 (published); Phase 3 underway — not approved
How does eloralintide compare with cagrilintide?
Both are long-acting amylin analogs injected once a week, and each is being developed alone and with a drug from the GLP-1 family: cagrilintide with semaglutide (CagriSema), eloralintide with tirzepatide (EloraTZP). The difference is selectivity. Cagrilintide activates amylin and calcitonin receptors alike; eloralintide was designed to prefer amylin receptors. No trial has compared the two in people as of November 2026, and their published results come from trials of different lengths, doses and populations, so the weight-loss figures don't line up directly. For a buyer the bigger difference is the record: cagrilintide has a long lab-test history on Peptigrity, while eloralintide is new to research shops, so a certificate that confirms identity by mass spectrometry matters as much as the purity figure. Two other amylin-based drugs are in development: petrelintide (Zealand Pharma and Roche) and amycretin (Novo Nordisk), which combines GLP-1 and amylin activity in one molecule. Pramlintide is the older, short-acting amylin analog approved as a mealtime add-on to insulin.
Sources: Is eloralintide a selective amylin receptor agonist?, Lilly Medical Information, via Lilly Medical Information (medical information answer); Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept, Briere D.A., Qu H., Lansu K., et al., Mol Metab, 2025
What are the known side effects and safety concerns?
In the Phase 2 trial the most common side effects were nausea and fatigue, mostly mild to moderate and more frequent at the higher doses; diarrhea and vomiting were also more common than on placebo at the higher doses. Serious adverse events occurred in 5.3% of people on eloralintide and 5.4% on placebo, and no one died. Longer-term safety, and safety in larger and more varied groups, will come from Phase 3; none of it has been published as of November 2026. Research-market vials add a risk the trials don't have: what is in them is known only from independent testing.
Source: Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial, Billings L.K., Hsia S., Bays H., et al., Lancet, 2025 · Evidence level: phase 2
Is Eloralintide FDA approved?
No. Eloralintide isn't approved by the FDA or any other regulator (verified Nov 2026). Eli Lilly is testing it for weight management in Phase 3 trials, and it's only available inside clinical trials. Anything sold as eloralintide by research shops isn't made by Eli Lilly, and what a vial contains is known only from an independent lab test.
Sources: ENLIGHTEN-1: eloralintide in adults with obesity or overweight without type 2 diabetes (NCT07321886), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in adults with obesity or overweight and type 2 diabetes (NCT07282600), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Eloralintide in obesity that persists on incretin therapy (NCT07392190), Eli Lilly and Company, via ClinicalTrials.gov (trial record); Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes, Eli Lilly and Company, via Eli Lilly and Company (company release, 30 Sep 2026)
How does Peptigrity verify Eloralintide?
Peptigrity collects independent third-party certificates of analysis (COAs) for eloralintide from shops' official channels and from buyers, and verifies each for authenticity before publishing. Because shops choose which certificates to publish, results reflect the batches shops have made public rather than every production batch, a selection bias we state openly. As with retatrutide and tirzepatide, eloralintide test results and prices don't name the shop unless the shop has chosen to be named; the lab, date, lot and results are always shown in full. For a compound this new to research shops, independent identity confirmation by mass spectrometry matters as much as purity: compare the mass a certificate reports with the molecular weight above.
This section is for educational and informational purposes only and does not constitute medical advice. Eloralintide is not approved by the FDA or equivalent regulators for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Frequently asked questions
Is eloralintide a GLP-1 drug?
No. Eloralintide acts on amylin receptors and doesn't act directly on GLP-1, GIP or glucagon receptors. Lilly is testing it alone and together with tirzepatide, which acts on GLP-1 and GIP receptors.
What's the difference between eloralintide and cagrilintide?
Both are long-acting amylin analogs injected once a week. Cagrilintide acts on amylin and calcitonin receptors alike; eloralintide was designed to prefer amylin receptors. No trial has compared them in people.
What is EloraTZP?
EloraTZP is Eli Lilly's name for eloralintide combined with tirzepatide. In a 48-week Phase 2b trial in adults with obesity or overweight and type 2 diabetes, the highest-dose combination produced 23.3% average weight loss, and Lilly plans Phase 3 trials of a single-injection version by the end of 2026. It isn't approved.
Is eloralintide legal to purchase?
It is not an approved product; research-market material is sold for research use only (RUO) and is unverified. Verify local rules.
Does Peptigrity recommend an eloralintide dose?
No. It is investigational and Peptigrity is an independent review platform, not a medical authority.
Why don't eloralintide lab tests name the shop?
Peptigrity treats eloralintide the way it treats retatrutide and tirzepatide: test results and prices are published without the shop's name unless the shop has chosen to be named. The lab, date, lot and results are always shown in full.
Eloralintide and other weight loss & metabolic peptides
| Compound | Mechanism | Avg purity | Tests | Shops |
|---|---|---|---|---|
| Eloralintide This page | Selective amylin receptor agonist (investigational) | 99.6% | 8 | 1 |
| Retatrutide | GLP-1 / GIP / Glucagon triple-agonist | 99.7% | 1,563 | 438 |
| Tirzepatide | GLP-1 / GIP dual-agonist | 99.8% | 1,136 | 386 |
| MOTS-C | Mitochondrial-derived metabolic peptide | 99.5% | 666 | 496 |
| Semaglutide | GLP-1 receptor agonist | 99.7% | 471 | 307 |
| Cagrilintide | Long-acting amylin receptor agonist | 99.6% | 296 | 305 |
| 5-Amino-1MQ | NNMT inhibitor (small molecule) | 99.6% | 196 | 367 |
| AOD-9604 | Direct adipocyte lipolysis (GH 176–191 analog) | 99.3% | 159 | 304 |
Community
No logs, questions or discussions about Eloralintide yet — early posts get the most eyes.
Have a lab test for Eloralintide?
Every submitted test helps the community verify purity across brands. Free, fast, independent.
Peptigrity is not affiliated with or endorsed by any manufacturer.